IRCT20171028037047N1 IRCT 2018-06-22 Bandare-abbas University of Medical Sciences Comparison of ezetimibe and atorvastatin treatment versus atorvastatin alone on Major Adverse Cardiac Events Comparison of ezetimibe and atorvastatin treatment versus atorvastatin alone on Major Adverse Cardiac Events (MACE) after elective percutaneous coronary intervention (PCI) 2018-02-04 anticipated 224 Complete https://irct.ir/trial/28808 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In randomized manner, every patient who goes to PCI will be included in the study if they have all the inclusion criteria and no exclusion ones. Then by tossing coin they will be randomly divided into intervention and non intervention groups, Blinding description: Patients in the first group receive atorvastatin 40 mg and ezetimibe 10 mg daily. In the second group, the placebo is given in the same dose as in the original package, with the same shape, color and size, and in a manner that is not differentiated from the original drug. Medications will be packaged in pre-prepared packages to patients so that patients and people who record the results of the study will be unaware of how the patients will be grouped. 4 Myocardial infarction. Intervention 1: Intervention group: Patients in this group receive atorvastatin 40 mg and ezetimibe 10 mg daily. Intervention 2: Control group: Patients in this group receive atorvastatin 40 mg and placebo 10 mg daily. The placebo is given in the same dose as in the original package, with the same shape, color and size, and in a manner, that is not differentiated from the original drug. No - There is not a plan to make this available Justification or reason for not sharing IPD is No more information